Literature DB >> 20971825

Notch signaling pathway as a therapeutic target in breast cancer.

Hamed Al-Hussaini1, Deepa Subramanyam, Michael Reedijk, Srikala S Sridhar.   

Abstract

The highly conserved Notch signaling pathway is involved in regulating a number of key cellular processes. This pathway has been implicated in both the development and progression of breast cancer and has emerged as a possible therapeutic target. Several clinical trials are currently underway to determine if targeting the Notch pathway with drugs such as the γ-secretase inhibitors may be an effective therapeutic strategy that improves outcomes in this disease. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20971825     DOI: 10.1158/1535-7163.MCT-10-0677

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  61 in total

1.  Bruceantin inhibits multiple myeloma cancer stem cell proliferation.

Authors:  Mark E Issa; Sarah Berndt; Gilles Carpentier; John M Pezzuto; Muriel Cuendet
Journal:  Cancer Biol Ther       Date:  2016-07-19       Impact factor: 4.742

Review 2.  Metastasis of circulating tumor cells: favorable soil or suitable biomechanics, or both?

Authors:  Ana Sofia Azevedo; Gautier Follain; Shankar Patthabhiraman; Sébastien Harlepp; Jacky G Goetz
Journal:  Cell Adh Migr       Date:  2015-08-27       Impact factor: 3.405

Review 3.  Targeting γ-secretase in breast cancer.

Authors:  Jianxun Han; Qiang Shen
Journal:  Breast Cancer (Dove Med Press)       Date:  2012-06-21

Review 4.  Therapeutic targets of triple-negative breast cancer: a review.

Authors:  Vinayak S Jamdade; Nikunj Sethi; Nitin A Mundhe; Parveen Kumar; Mangala Lahkar; Neeraj Sinha
Journal:  Br J Pharmacol       Date:  2015-07-30       Impact factor: 8.739

5.  NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation.

Authors:  M P Licciardello; M K Müllner; G Dürnberger; C Kerzendorfer; B Boidol; C Trefzer; S Sdelci; T Berg; T Penz; M Schuster; C Bock; R Kralovics; G Superti-Furga; J Colinge; S M Nijman; S Kubicek
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

6.  Paris Saponin II inhibits colorectal carcinogenesis by regulating mitochondrial fission and NF-κB pathway.

Authors:  Meihong Chen; Ke Ye; Biying Zhang; Qiao Xin; Ping Li; Ah-Ng Kong; Xiaodong Wen; Jie Yang
Journal:  Pharmacol Res       Date:  2018-11-22       Impact factor: 7.658

7.  Inhibition of notch pathway signaling: a one compound mission to treat cancer.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2013-03-01       Impact factor: 4.345

8.  Notch3 negatively regulates chemoresistance in breast cancers.

Authors:  Xiaoting Gu; Chunxiao Lu; Dongxu He; Yangfan Lu; Jian Jin; Dequan Liu; Xin Ma
Journal:  Tumour Biol       Date:  2016-10-14

Review 9.  Non-Coding RNAs as Regulators and Markers for Targeting of Breast Cancer and Cancer Stem Cells.

Authors:  Kirti S Prabhu; Afsheen Raza; Thasni Karedath; Syed Shadab Raza; Hamna Fathima; Eiman I Ahmed; Shilpa Kuttikrishnan; Lubna Therachiyil; Michal Kulinski; Said Dermime; Kulsoom Junejo; Martin Steinhoff; Shahab Uddin
Journal:  Cancers (Basel)       Date:  2020-02-04       Impact factor: 6.639

10.  Reinforcing targeted therapeutics with phenotypic stability factors.

Authors:  Paul Yaswen
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.